MedTrace Logo

Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy

NCT00311870 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2006-04-06

No results posted yet for this study

Summary

The aim of the study was to compare the renoprotective effect of a long acting calcium antagonist (nisoldipine) with an angiotensin converting enzyme inhibitor (lisinopril)in type 1 diabetic patients with diabetic kidney disease. In total, 51 patients were randomised to treatment with one of these drugs for 4 years. Changes in kidney function, blood pressure and urinary excretion of albumin were measured every 6 months

Conditions

  • Diabetic Nephropathy

Interventions

DRUG

nisoldipine

DRUG

lisinopril

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Steno Diabetes Center Copenhagen

    lead OTHER

Principal Investigators

  • Peter Rossing, MD · Steno Diabetes Center Copenhagen

  • Hans-Henrik Parving, MD · Steno Diabetes Center Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1993-03-31
Completion
1999-04-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00311870 on ClinicalTrials.gov